| Primary information |
|---|
| sequence ID | Seq_5757 |
| Peptide sequence | NRGDSTFESKSYKM |
| CancerPDF_ID | CancerPDF_ID551, CancerPDF_ID1327, CancerPDF_ID9737, CancerPDF_ID9738, CancerPDF_ID12722, |
| PMID | 19795908,21136997,21533267,21533267,27058005 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Plasma,Serum,Serum,Serum,Serum |
| M/Z | "825.38, 550.59",1648.75152,550.6,555.92,1665.957 |
| Charge | "2, 3",1,3,3,NA |
| Mass (in Da) | NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC/MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,Multiple Reaction Monitoring,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,1.49,1.49,NA |
| CancerPDF_ID | CancerPDF_ID551, CancerPDF_ID1327, CancerPDF_ID9737, CancerPDF_ID9738, CancerPDF_ID12722, |
| p-Value | NA,NA,NA,NA,"less than 0.01,0.418,0.394" |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT,MASCOT,Proteome Discoverer |
| Length | 14,14,14,14,14 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Lung adenocarcinoma,Lung adenocarcinoma,Breast cancer |
| Database | NCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4),Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,Oxidation,Oxidation (M) |
| Number of Patients | "42 normal, 28patients",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 0.65 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.06, Upregulated in BC vs healthy with 1.083 fold change" |
| Validation | NA,Leave One out Cross validation,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates,NA |
| Sensitivity | NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |